Phase I/II Study of Azacitidine, Docetaxel, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy

The combination of azacitidine, docetaxel, and prednisone with growth factor support is active in mCRPC patients.